Analysis of:
Drugs to Build Bones May Weaken Them (www.nytimes.com)
Patients may ask about this. Haven't heard anyone yet.
Analysis of:
Most Doctors Aren’t Using Electronic Health Records (www.nytimes.com)
EMRs are quite expensive, possibly one of the bigger outlays of cash I can think of. EMRs are also a work in evolution, much like operating software: who wants to invest a lot of money on Vista when rumors of a new and better program are out there? The enormous stress of putting one...
Analysis of:
AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six (www.pipelinereview.com)
Good drug with rapid onset. ? if will create some confusion with adult dosing
Analysis of:
New data show Tekturna HCT® is twice as effective at reducing blood pressure than the diuretic HCT alone (www.novartis.com)
I have used this medication a few times and, although good, it is not a powerhouse like some others. It looks to me as if the claim of "double" the potency with HCTZ is more smoke and mirrors.
Analysis of:
New data show Tekturna HCT® is twice as effective at reducing blood pressure than the diuretic HCT alone (www.novartis.com)
I think the long affect of Aliskiren (3-4 days ) after the last pill is both a benefit and a risk; it is good in the setting on noncompliance but quite a challenge when trying to reverse the hypotensive effects in emergency situation. It is interesting that it is more effective...
Analysis of:
Lipitor Provided an Unexpectedly Potent Heart Benefit in Patients with Chronic Stable Angina, According to New Study (www.pipelinereview.com)
Lipitor is the only statin tested to reduce ischemic stroke. The new study also proved its role in reduce angina and MI
Analysis of:
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease (www.fiercebiotech.com)
LY450139 acts through decrease the production of amyloid beta, the protein found in some of AD pathology. This novel mechanism of action carries the hope of halting disease progression.
Analysis of:
Google to store patients' health records (news.yahoo.com)
Google will expect a profit from this venture meaning revenue may eventually come from selling the service itself but data mining and selling that data is likely to be far more profitable. Patients should be wary of having their information used for reasons other than their care. ...
Analysis of:
Ceregene Presents Long-Term Follow-Up from Phase 1 Trial of CERE-120 in Parkinson's Disease (www.pipelinereview.com)
It is exciting to hear about the effectiveness of CERE-120 in advanced Parkinson's disease.